US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Intensity Therapeutics, Inc.

0.4485

-0.0235-4.98%

Volume:190.69K

Turnover:83.86K

Market Cap:8.25M

PE:-0.43

High:0.4800

Open:0.4800

Low:0.4260

Close:0.4720

Loading ...

Overview Company News Filings

BRIEF-Intensity Therapeutics to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy

Intensity Therapeutics, Inc. to Collaborate With Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon

THOMSON REUTERS

Intensity Therapeutics Inc. Faces Potential Nasdaq Delisting Due to Non-Compliance with Stockholders' Equity Requirement

Brookline Capital Downgrades Intensity Therapeutics to Hold From Buy

MT Newswires Live

BRIEF-Intensity Therapeutics Q1 Basic EPS USD -0.22

Intensity Therapeutics Inc. Reports Q1 2025 Net Loss of $3.3 Million, Down from $4.6 Million in Q1 2024; Revenue Details Unspecified

Intensity Therapeutics Q1 Basic EPS USD -0.22

THOMSON REUTERS

Wall Street Set to Open Lower Friday Amid Slew of Earnings Reports

MT Newswires Live

Investors Parse Earnings Reports as US Futures Dip in Fridays Premarket

MT Newswires Live

Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering

Is Cencora, Inc. (COR) Outperforming Other Medical Stocks This Year?

Has Cencora, Inc. (COR) Outpaced Other Medical Stocks This Year?

Press Release: Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update

Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("Invincible-3 Study") Following Periodic Review

THOMSON REUTERS

Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review

Intensity Therapeutics Inc : Alliance Global Partners Initiates Coverage With Buy Rating; Target Price $8.5

THOMSON REUTERS

Intensity Therapeutics Provides Business Update Highlighting Key Achievements With Lead Drug Candidate Int230-6

THOMSON REUTERS

Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6

Intensity Therapeutics Says Stockholder Armistice Capital May Sell 1.24 Million Shares

MT Newswires Live

Intensity Therapeutics Says Cancer Drug Candidate Shows Benefits in Phase 2 Trial

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/INTS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"INTS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INTS\",,,,,undefined,":{"symbol":"INTS","market":"US","secType":"STK","nameCN":"Intensity Therapeutics, Inc.","latestPrice":0.4485,"timestamp":1749153600000,"preClose":0.472,"halted":0,"volume":190692,"delay":0,"floatShares":10073700,"shares":18398202,"eps":-1.051783,"marketStatus":"Pre-Mkt","change":-0.0235,"latestTime":"06-06 05:23:59 EDT","open":0.48,"high":0.48,"low":0.426,"amount":83855.14416576001,"amplitude":0.114407,"askPrice":0.4485,"askSize":900,"bidPrice":0.3432,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.051783,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1749216600000},"marketStatusCode":1,"adr":0,"listingDate":1666324800000,"exchange":"NASDAQ","adjPreClose":0.4485,"postHourTrading":{"tag":"盘后","latestPrice":0.4479,"preClose":0.4485,"latestTime":"19:18 EDT","volume":8082,"amount":3555.2735,"timestamp":1749165496822},"volumeRatio":0.06112754960217424},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INTS\",,,,,undefined,":{"symbol":"INTS","floatShares":10073700,"roa":"-123.09%","roe":"-298.57%","lyrEps":-1.169772,"volumeRatio":0.06112754960217424,"shares":18398202,"dividePrice":0,"high":0.48,"amplitude":0.114407,"preClose":0.472,"low":0.426,"week52Low":0.29,"pbRate":"24.71","week52High":5.1,"institutionHeld":0,"latestPrice":0.4485,"committee":-0.8,"eps":-1.051783,"divideRate":0,"volume":190692,"delay":0,"ttmEps":-1.051783,"open":0.48,"prevYearClose":1.76,"prevWeekClose":0.4752,"prevMonthClose":0.4752,"prevQuarterClose":1.97,"fiveDayClose":0.389,"twentyDayClose":0.5512,"sixtyDayClose":2.36},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"INTS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2538471644","title":"BRIEF-Intensity Therapeutics to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy","url":"https://stock-news.laohu8.com/highlight/detail?id=2538471644","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538471644?lang=en_us&edition=fundamental","pubTime":"2025-05-28 21:39","pubTimestamp":1748439588,"startTime":"0","endTime":"0","summary":"BRIEF-Intensity Therapeutics to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy May 28 (Reuters) - Intensity Therapeutics Inc INTS.O:INTENSITY TH","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nTUABGSHQS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INTS"],"gpt_icon":0},{"id":"2538473714","title":"Intensity Therapeutics, Inc. to Collaborate With Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon","url":"https://stock-news.laohu8.com/highlight/detail?id=2538473714","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538473714?lang=en_us&edition=fundamental","pubTime":"2025-05-28 20:00","pubTimestamp":1748433607,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nTUABGSHQS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INTS","BK4139"],"gpt_icon":0},{"id":"2537628029","title":"Intensity Therapeutics Inc. Faces Potential Nasdaq Delisting Due to Non-Compliance with Stockholders' Equity Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2537628029","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537628029?lang=en_us&edition=fundamental","pubTime":"2025-05-21 04:07","pubTimestamp":1747771631,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics Inc. announced on May 19, 2025, that it received a notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC, indicating the company is not in compliance with the minimum stockholders' equity requirement necessary for continued listing on The Nasdaq Capital Market. The notice follows the company's latest quarterly report, which revealed it did not meet the Nasdaq Listing Rule 5550 criteria. Intensity Therapeutics has until July 3, 2025, to submit a plan to regain compliance. If accepted, the company could receive a 180-day extension to meet the requirements. The notice does not immediately affect the company's listing, but failure to comply may lead to delisting, subject to appeal.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interprete","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nNDL2FXBf9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INTS"],"gpt_icon":0},{"id":"2536463671","title":"Brookline Capital Downgrades Intensity Therapeutics to Hold From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2536463671","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536463671?lang=en_us&edition=fundamental","pubTime":"2025-05-20 00:17","pubTimestamp":1747671455,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics (INTS) has an average rating of overweight and mean price target of $6.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research f","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BRKL","INTS"],"gpt_icon":0},{"id":"2535087161","title":"BRIEF-Intensity Therapeutics Q1 Basic EPS USD -0.22","url":"https://stock-news.laohu8.com/highlight/detail?id=2535087161","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535087161?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:41","pubTimestamp":1747168902,"startTime":"0","endTime":"0","summary":"BRIEF-Intensity Therapeutics Q1 Basic EPS USD -0.22May 13 (Reuters) - Intensity Therapeutics Inc INTS.O:INTENSITY THERAPEUTICS Q1 BASIC EPS USD -0.22INTENSITY THERAPEUTICS Q1 OPERATING INCOME USD -3.3","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nPLX1AA8BC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INTS"],"gpt_icon":0},{"id":"2535325084","title":"Intensity Therapeutics Inc. Reports Q1 2025 Net Loss of $3.3 Million, Down from $4.6 Million in Q1 2024; Revenue Details Unspecified","url":"https://stock-news.laohu8.com/highlight/detail?id=2535325084","media":"Reuters","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535325084?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:08","pubTimestamp":1747166886,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics Inc. Reports Q1 2025 Net Loss of $3.3 Million, Down from $4.6 Million in Q1 2024; Revenue Details Unspecified. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intensity Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on May 13, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nNDL9lHSqd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INTS"],"gpt_icon":0},{"id":"2535810600","title":"Intensity Therapeutics Q1 Basic EPS USD -0.22","url":"https://stock-news.laohu8.com/highlight/detail?id=2535810600","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535810600?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:06","pubTimestamp":1747166793,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nPLX1AA8BC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INTS","BK4139"],"gpt_icon":0},{"id":"2530613504","title":"Wall Street Set to Open Lower Friday Amid Slew of Earnings Reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2530613504","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530613504?lang=en_us&edition=fundamental","pubTime":"2025-04-25 21:18","pubTimestamp":1745587126,"startTime":"0","endTime":"0","summary":"Group  lost 19%, eating half of Thursday's 38% gain.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OMEX","INTS","PET","SES","CIA","BCTX","PONY","SAIA"],"gpt_icon":1},{"id":"2530182668","title":"Investors Parse Earnings Reports as US Futures Dip in Fridays Premarket","url":"https://stock-news.laohu8.com/highlight/detail?id=2530182668","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530182668?lang=en_us&edition=fundamental","pubTime":"2025-04-25 20:07","pubTimestamp":1745582848,"startTime":"0","endTime":"0","summary":"US stock futures were tracking lower in Friday's premarket session ahead of the University of Michigan's consumer sentiment and expectations index readings, which are set to be released at 10:00 am EDT.Dow Jones Industrial Average futures were down 0.4%, S&P 500 futures were off 0.2%, and Nasdaq futures were moving 0.3% lower.Oil prices were moving lower, with front-month global benchmarks North Sea Brent falling 1.2% to $64.85 per barrel, and US West Texas Intermediate crude falling 1.2% to $62.02 per barrel.Both the Michigan Consumer Sentiment and the Michigan Consumer Expectations indices for April are expected to drop sharply, with the former forecast to fall to 50.8 from 57.0 in March, while the latter is projected to drop to 47.2 from 52.6, according to Bloomberg.In equities, shares of Odyssey Marine Exploration  surged 36%, adding to a 100% gain the previous session. Cantor Equity Partners  shares added 16%, after advancing 50% Thursday. And shares of American Rebel  climbed 15%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["INTS","OMEX","CIA","ISBC","AREB","CEP","FBRX"],"gpt_icon":1},{"id":"2530182844","title":"Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2530182844","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530182844?lang=en_us&edition=fundamental","pubTime":"2025-04-25 20:00","pubTimestamp":1745582400,"startTime":"0","endTime":"0","summary":"SHELTON, Conn., April 25, 2025 /PRNewswire/ --Intensity Therapeutics, Inc. ,  a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced the pricing of its \"reasonable best efforts\" public offering with participation from certain new and existing institutional and accredited investors for the purchase and sale of 3,133,333 shares of its common stock  and accompanying Series B-1 common warrants to purchase up to 3,133,333 shares of common stock and Series B-2 common warrants to purchase up to 3,133,333 shares of common stock at a combined purchase price per share and accompanying common warrants of $0.75 .This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which su","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/intensity-therapeutics-inc-announces-2-120000280.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/intensity-therapeutics-inc-announces-2-120000280.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["INTS","BK4139"],"gpt_icon":0},{"id":"2529564382","title":"Is Cencora, Inc. (COR) Outperforming Other Medical Stocks This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2529564382","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529564382?lang=en_us&edition=fundamental","pubTime":"2025-04-21 21:40","pubTimestamp":1745242809,"startTime":"0","endTime":"0","summary":"The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Cencora  been one of those stocks this year?Let's take a closer look at the stock's year-to-date performance to find out.Cencora is a member of our Medical group, which includes 1002 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Cencora is currently sporting a Zacks Rank of #2 .Intensity Therapeutics Inc.  is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cencora-inc-cor-outperforming-other-134009430.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["COR","INTS"],"gpt_icon":0},{"id":"2524136264","title":"Has Cencora, Inc. (COR) Outpaced Other Medical Stocks This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2524136264","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524136264?lang=en_us&edition=fundamental","pubTime":"2025-04-03 21:40","pubTimestamp":1743687611,"startTime":"0","endTime":"0","summary":"For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Cencora  been one of those stocks this year?By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Cencora is a member of the Medical sector. This group includes 1005 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Cencora is currently sporting a Zacks Rank of #2 .Intensity Therapeutics Inc.  is another Medical stock that has o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cencora-inc-cor-outpaced-other-134011736.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","SG9999004303.SGD","LU0289739699.SGD","BK4084","COR","LU1261432733.SGD","LU1430594728.SGD","LU2237957902.USD","BK4139","LU1084165304.USD","SGXZ23171101.USD","LU1585245621.USD","INTS","LU2324357040.USD","BK4529","LU1119994496.HKD","BK4175","LU2237957811.SGD","BK4585","LU0058720904.USD"],"gpt_icon":1},{"id":"2519869410","title":"Press Release: Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2519869410","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519869410?lang=en_us&edition=fundamental","pubTime":"2025-03-14 04:07","pubTimestamp":1741896420,"startTime":"0","endTime":"0","summary":"-- 32 sites are currently contracted in the INVINCIBLE-3 Study, and 25. -- Eight Swiss sites are activated in the INVINCIBLE-4 Study, and several. Study design was presented at the annual Connective Tissue Oncology. INVINCIBLE-4 Study design was presented at the annual San Antonio Breast. In July 2024, the Company initiated and dosed its first patient in the INVINCIBLE-3 Study.  The trial is actively enrolling patients across the US, Canada, Europe and Australia. Up to 60 sarcoma-focused institutions are expected to participate from these regions. The Company has contracted 32 sites with 25 patients screened to date.  The Company expects to complete enrollment in the first half of 2026.In October 2024, in collaboration with The Swiss Group for Cancer Research SAKK , the Company initiated and dosed its first patient in Switzerland in the INVINCIBLE-4 Study. To date, the Company has activated eight sites in Switzerland and treat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2360107325.USD","LU2298322129.HKD","LU0348723411.USD","LU1854103824.USD","LU1861215975.USD","ON","LU1861219969.SGD","BK4141","LU0124384867.USD","LU1861220033.SGD","LENZ","LU1861214812.USD","LU1720051017.SGD","BK4585","LU1978683503.SGD","BK4605","BK4139","LU1854104046.USD","LU1548497426.USD","IE00BZ199S13.USD","LU1720051108.HKD","LU0724618433.USD","LU2357305700.SGD","BK4512","INTS","IE00BD6J9T35.USD","BK4588"],"gpt_icon":0},{"id":"2506518045","title":"Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial (\"Invincible-3 Study\") Following Periodic Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2506518045","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506518045?lang=en_us&edition=fundamental","pubTime":"2025-01-28 21:00","pubTimestamp":1738069208,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250128:nTUA1RF0W8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INTS","BK4139"],"gpt_icon":0},{"id":"2506130975","title":"Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial (\"INVINCIBLE-3 Study\") Following Periodic Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2506130975","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506130975?lang=en_us&edition=fundamental","pubTime":"2025-01-28 21:00","pubTimestamp":1738069200,"startTime":"0","endTime":"0","summary":"SHELTON, Conn., Jan. 28, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ,  a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces that following its most recent periodic review meeting, the Data Monitoring Committee  overseeing the Company's ongoing Phase 3 sarcoma study of INT230-6   has agreed that the study should continue without modification. TheDMC reviewed data covering the six months from July to December 2024.\"The Data Monitoring Committee is designed to confidentially review data to determine whether safety concerns with the data collected to date exist. We are encouraged by the continuation of the trial and continue to believe that INT230-6 represents important potential in a treatment area that has significantly unmet medical need. We look forward to continuing enrollment and to providing furth","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/drug-monitoring-committee-authorizes-continuation-130000116.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/drug-monitoring-committee-authorizes-continuation-130000116.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","LU2517655028.SGD","BK4134","BK4139","LU1814569148.SGD","LU2517655374.HKD","LU0154245673.USD","INTS","LU2517655291.USD","LU0154245756.USD","BK4588","LU0107464264.USD","LENZ","IT"],"gpt_icon":0},{"id":"2503930844","title":"Intensity Therapeutics Inc : Alliance Global Partners Initiates Coverage With Buy Rating; Target Price $8.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2503930844","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503930844?lang=en_us&edition=fundamental","pubTime":"2025-01-13 20:03","pubTimestamp":1736769780,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nFWN3O90YY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INTS","BK4139"],"gpt_icon":0},{"id":"2502868288","title":"Intensity Therapeutics Provides Business Update Highlighting Key Achievements With Lead Drug Candidate Int230-6","url":"https://stock-news.laohu8.com/highlight/detail?id=2502868288","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502868288?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:00","pubTimestamp":1736514005,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nTUA5RRXFY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INTS","BK4139"],"gpt_icon":0},{"id":"2502667865","title":"Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6","url":"https://stock-news.laohu8.com/highlight/detail?id=2502667865","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502667865?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:00","pubTimestamp":1736514000,"startTime":"0","endTime":"0","summary":"The US FDA, Health Canada, European Medicines Authority, and the Australian Therapeutic Goods Administration authorized the Company's global, randomized Phase 3 study  in Metastatic Soft Tissue Sarcoma. Twenty-three sites are currently contracted in the INVINCIBLE 3 study, and several sites have treated patients. Seven Swiss sites are activated in the Phase 2  study for early-stage, operable Triple Negative Breast Cancer , and several patients have been treated. SHELTON, Conn., Jan. 10, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. , a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announces a business update highlighting key achievements with its lead drug candidate INT230-6.In October 2024, the Company, in collaboration with the Swiss Group for Clinical Cancer Research SAKK  in the INVINCIBLE-4 Study,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/intensity-therapeutics-provides-business-highlighting-130000009.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/intensity-therapeutics-provides-business-highlighting-130000009.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4534","BK4213","LU0320765646.SGD","LU1585245621.USD","PR","LU2237438978.USD","IE00B7SZLL34.SGD","IE00B19Z3B42.SGD","BK4559","IE0002270589.USD","LU0149725797.USD","LU0320765489.SGD","BK4585","IE00BFSS8Q28.SGD","BK4588","LU1162221912.USD","LU1430594728.SGD","CTOS","LU2133065610.SGD","LU1074936037.SGD","LU0211331839.USD","BK4104","BK4550","LU0061475181.USD","LU0070302665.USD","IE00B19Z3581.USD","IE00BJJMRY28.SGD","IE00B7KXQ091.USD","BK4131","UPS","IE0004445015.USD","IE00BFSS7M15.SGD","BK4139","IE00BJJMRX11.SGD","INTS","BK4532","LU0208291251.USD","LENZ"],"gpt_icon":0},{"id":"2491958650","title":"Intensity Therapeutics Says Stockholder Armistice Capital May Sell 1.24 Million Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2491958650","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491958650?lang=en_us&edition=fundamental","pubTime":"2024-12-14 05:48","pubTimestamp":1734126497,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics  said stockholder Armistice Capital may offer and resell almost 1.24 million shares.The shareholder will get all of the proceeds from any sales, Intensity Therapeutics said Friday in a regulatory filing.The timing and amount of any sale are at the sole discretion of Armistice.The shares of Intensity Therapeutics fell 2.9% in after-hours trading.Price: 2.00, Change: -0.06, Percent Change: -2.91","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","INTS","LENZ"],"gpt_icon":0},{"id":"2491336877","title":"Intensity Therapeutics Says Cancer Drug Candidate Shows Benefits in Phase 2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2491336877","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491336877?lang=en_us&edition=fundamental","pubTime":"2024-12-13 00:26","pubTimestamp":1734020771,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics  and The Swiss Group for Clinical Cancer Research, or SAKK, said Thursday that cancer drug candidate INT230-6 showed several benefits in a phase 2 trial in multiple tumor types, including triple negative breast cancer.INT230-6, designed for direct intratumoral injection, leads to local disease control and direct tumor killing as well as has systemic anti-tumor effects, according to a joint statement.Data from the study showed that INT230-6 has tumor-killing properties at levels greater than 95% in some patients treated with a single dose, as well as \"significant\" necrosis in tumors bigger than 2 cm in 74% of the patients at the time of surgery, the company and SAKK said.Intensity and SAKK have also initiated a phase 2 study to assess the clinical activity, safety and tolerability of INT230-6 in patients with early-stage, operable triple negative breast cancer. Recruitment is ongoing, with a target to enroll 54 patients, and seven sites have been activated in Swit","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","INTS","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":22,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/INTS\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"INTS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"INTS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.8,"hold":0.2,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8,"analysts":5,"updateTime":1747713600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/INTS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"INTS","date":"2025-06-04","current":-0.626387,"percent":0.945534,"low":-15.25821,"twenty":-7.341855,"median":-4.64843,"eighty":-2.102094,"high":-0.31723,"avg":-5.05172,"sd":3.291428,"marketCap":9403321},"quantilePoints":[{"date":"2022-10-20","current":-9.173693,"twenty":-9.173693,"median":-9.173693,"eighty":-9.173693,"marketCap":80934718},{"date":"2023-07-07","current":-12.000673,"twenty":-12.000673,"median":-11.893737,"eighty":-9.173693,"marketCap":78596262},{"date":"2023-07-14","current":-11.805305,"twenty":-12.014248,"median":-11.893737,"eighty":-11.600651,"marketCap":77316730},{"date":"2023-07-21","current":-12.682867,"twenty":-12.306769,"median":-11.947205,"eighty":-11.660654,"marketCap":83064168},{"date":"2023-07-28","current":-11.867988,"twenty":-12.682867,"median":-12.014248,"eighty":-11.805305,"marketCap":77727261},{"date":"2023-08-04","current":-12.81868,"twenty":-12.682867,"median":-12.066484,"eighty":-11.867988,"marketCap":83953652},{"date":"2023-08-11","current":-12.933599,"twenty":-12.933599,"median":-12.306769,"eighty":-11.888882,"marketCap":84706293},{"date":"2023-08-18","current":-9.652146,"twenty":-12.81868,"median":-12.1197,"eighty":-11.660654,"marketCap":80327292},{"date":"2023-08-25","current":-9.800135,"twenty":-12.808233,"median":-12.000673,"eighty":-9.800135,"marketCap":81558886},{"date":"2023-09-01","current":-9.487714,"twenty":-12.770623,"median":-11.912204,"eighty":-9.783692,"marketCap":78958855},{"date":"2023-09-08","current":-9.093078,"twenty":-12.755579,"median":-11.893737,"eighty":-9.638992,"marketCap":75674604},{"date":"2023-09-15","current":-8.073601,"twenty":-12.70794,"median":-11.836647,"eighty":-9.487714,"marketCap":67190291},{"date":"2023-09-22","current":-6.034647,"twenty":-12.632721,"median":-11.600651,"eighty":-9.000996,"marketCap":50221663},{"date":"2023-09-29","current":-6.626601,"twenty":-12.586753,"median":-9.923459,"eighty":-8.293939,"marketCap":55148039},{"date":"2023-10-06","current":-7.251442,"twenty":-12.570873,"median":-9.800135,"eighty":-7.560574,"marketCap":60348102},{"date":"2023-10-13","current":-6.626601,"twenty":-12.448015,"median":-9.783692,"eighty":-7.192246,"marketCap":55148039},{"date":"2023-10-20","current":-4.636976,"twenty":-12.331842,"median":-9.61926,"eighty":-6.745518,"marketCap":38589943},{"date":"2023-10-23","current":-4.96584,"twenty":-12.319306,"median":-9.578152,"eighty":-6.686849,"marketCap":41326818},{"date":"2023-11-03","current":-4.932954,"twenty":-12.157898,"median":-9.487714,"eighty":-6.567406,"marketCap":41053131},{"date":"2023-11-10","current":-4.609845,"twenty":-12.119112,"median":-9.173693,"eighty":-6.48519,"marketCap":38364150},{"date":"2023-11-17","current":-3.237228,"twenty":-12.035142,"median":-8.862874,"eighty":-6.287872,"marketCap":28737191},{"date":"2023-11-24","current":-3.590621,"twenty":-12.006103,"median":-8.517567,"eighty":-5.189368,"marketCap":31874301},{"date":"2023-12-01","current":-3.784438,"twenty":-11.971208,"median":-8.209257,"eighty":-5.01517,"marketCap":33594828},{"date":"2023-12-08","current":-6.177413,"twenty":-11.939029,"median":-7.613192,"eighty":-5.01517,"marketCap":54837508},{"date":"2023-12-15","current":-12.447487,"twenty":-12.056037,"median":-8.209257,"eighty":-5.034902,"marketCap":110497578},{"date":"2023-12-22","current":-9.544103,"twenty":-12.056037,"median":-8.517567,"eighty":-5.074891,"marketCap":84723949},{"date":"2023-12-29","current":-12.200391,"twenty":-12.097826,"median":-8.854652,"eighty":-5.093498,"marketCap":108304078},{"date":"2024-01-05","current":-12.586479,"twenty":-12.221667,"median":-9.093078,"eighty":-5.095649,"marketCap":111731422},{"date":"2024-01-12","current":-9.080797,"twenty":-12.136622,"median":-9.173576,"eighty":-5.162954,"marketCap":80611136},{"date":"2024-01-19","current":-7.443783,"twenty":-12.119504,"median":-9.086938,"eighty":-5.189368,"marketCap":66079197},{"date":"2024-01-26","current":-6.94959,"twenty":-12.056037,"median":-8.862874,"eighty":-5.265897,"marketCap":61692196},{"date":"2024-02-02","current":-7.706323,"twenty":-12.006103,"median":-8.582973,"eighty":-5.358906,"marketCap":68409791},{"date":"2024-02-09","current":-5.497898,"twenty":-11.971208,"median":-8.279141,"eighty":-5.454656,"marketCap":48805382},{"date":"2024-02-16","current":-4.67939,"twenty":-11.939029,"median":-8.106172,"eighty":-5.189368,"marketCap":41539412},{"date":"2024-02-23","current":-4.63306,"twenty":-11.915897,"median":-7.791263,"eighty":-5.065946,"marketCap":41128131},{"date":"2024-03-01","current":-5.714107,"twenty":-11.893737,"median":-7.613192,"eighty":-5.065946,"marketCap":50724694},{"date":"2024-03-08","current":-8.617491,"twenty":-11.891795,"median":-7.659757,"eighty":-5.094215,"marketCap":76498323},{"date":"2024-03-15","current":-6.42451,"twenty":-11.880524,"median":-7.613192,"eighty":-5.12966,"marketCap":57031008},{"date":"2024-03-22","current":-7.168217,"twenty":-11.842915,"median":-7.462714,"eighty":-5.183371,"marketCap":75538667},{"date":"2024-03-28","current":-6.569781,"twenty":-11.793205,"median":-7.382998,"eighty":-5.190398,"marketCap":69232353},{"date":"2024-04-05","current":-6.062412,"twenty":-11.727976,"median":-7.320234,"eighty":-5.219219,"marketCap":63885696},{"date":"2024-04-12","current":-5.919308,"twenty":-11.648653,"median":-7.270395,"eighty":-5.328019,"marketCap":62377665},{"date":"2024-04-19","current":-4.956607,"twenty":-11.467325,"median":-7.168217,"eighty":-5.219219,"marketCap":52232726},{"date":"2024-04-26","current":-5.106216,"twenty":-10.872247,"median":-7.057617,"eighty":-5.181486,"marketCap":53809304},{"date":"2024-05-03","current":-5.203787,"twenty":-10.575732,"median":-7.004794,"eighty":-5.110119,"marketCap":54837508},{"date":"2024-05-10","current":-4.89156,"twenty":-10.334812,"median":-6.920091,"eighty":-5.07751,"marketCap":51547257},{"date":"2024-05-17","current":-5.064674,"twenty":-10.138832,"median":-6.816961,"eighty":-5.04775,"marketCap":69917822},{"date":"2024-05-24","current":-5.034882,"twenty":-10.040205,"median":-6.769756,"eighty":-5.01517,"marketCap":69506541},{"date":"2024-05-31","current":-4.905782,"twenty":-10.013896,"median":-6.720408,"eighty":-4.982612,"marketCap":67724322},{"date":"2024-06-07","current":-4.945811,"twenty":-9.945635,"median":-6.626601,"eighty":-4.965367,"marketCap":68276920},{"date":"2024-06-14","current":-4.747756,"twenty":-9.859151,"median":-6.577272,"eighty":-4.943699,"marketCap":65542772},{"date":"2024-06-21","current":-4.638498,"twenty":-9.834825,"median":-6.527942,"eighty":-4.905297,"marketCap":64034465},{"date":"2024-06-28","current":-4.887408,"twenty":-9.833021,"median":-6.527942,"eighty":-4.896744,"marketCap":67470661},{"date":"2024-07-05","current":-4.817184,"twenty":-9.806712,"median":-6.504734,"eighty":-4.887289,"marketCap":66501232},{"date":"2024-07-12","current":-4.986137,"twenty":-9.800135,"median":-6.468725,"eighty":-4.878216,"marketCap":68833622},{"date":"2024-07-15","current":-5.055665,"twenty":-9.800135,"median":-6.445726,"eighty":-4.87855,"marketCap":69793453},{"date":"2024-08-02","current":-4.807351,"twenty":-9.796846,"median":-6.435118,"eighty":-4.877213,"marketCap":66365484},{"date":"2024-08-09","current":-4.588835,"twenty":-9.783692,"median":-6.41284,"eighty":-4.86516,"marketCap":63348871},{"date":"2024-08-16","current":-3.955696,"twenty":-9.783692,"median":-6.339457,"eighty":-4.820512,"marketCap":59632119},{"date":"2024-08-23","current":-3.896315,"twenty":-9.757383,"median":-6.270563,"eighty":-4.807351,"marketCap":58736948},{"date":"2024-08-30","current":-3.86434,"twenty":-9.645569,"median":-6.204474,"eighty":-4.781352,"marketCap":58254933},{"date":"2024-09-06","current":-3.910018,"twenty":-9.61926,"median":-6.112191,"eighty":-4.747756,"marketCap":58943526},{"date":"2024-09-13","current":-3.837391,"twenty":-9.544103,"median":-6.034647,"eighty":-4.707926,"marketCap":57848664},{"date":"2024-09-20","current":-3.727307,"twenty":-9.537044,"median":-5.97785,"eighty":-4.668296,"marketCap":56189156},{"date":"2024-09-27","current":-3.316207,"twenty":-9.52866,"median":-5.925812,"eighty":-4.63306,"marketCap":49991822},{"date":"2024-10-04","current":-3.2888,"twenty":-9.487714,"median":-5.784184,"eighty":-4.588835,"marketCap":49578667},{"date":"2024-10-11","current":-3.037299,"twenty":-9.487714,"median":-5.559672,"eighty":-4.472545,"marketCap":45787276},{"date":"2024-10-18","current":-2.923378,"twenty":-9.487714,"median":-5.461423,"eighty":-4.216084,"marketCap":44069926},{"date":"2024-10-25","current":-2.923378,"twenty":-9.26612,"median":-5.333882,"eighty":-3.973967,"marketCap":44069926},{"date":"2024-10-31","current":-2.786345,"twenty":-9.192178,"median":-5.307863,"eighty":-3.960154,"marketCap":42004148},{"date":"2024-11-08","current":-2.941649,"twenty":-9.173693,"median":-5.199834,"eighty":-3.926462,"marketCap":44345363},{"date":"2024-11-15","current":-2.689442,"twenty":-9.173505,"median":-5.189027,"eighty":-3.893574,"marketCap":43725630},{"date":"2024-11-22","current":-2.507825,"twenty":-9.109154,"median":-5.115973,"eighty":-3.863938,"marketCap":40772862},{"date":"2024-11-29","current":-2.717615,"twenty":-9.085709,"median":-5.101291,"eighty":-3.84881,"marketCap":44185701},{"date":"2024-12-06","current":-2.321954,"twenty":-9.052999,"median":-5.073692,"eighty":-3.799491,"marketCap":37752650},{"date":"2024-12-13","current":-1.917562,"twenty":-8.931511,"median":-5.06017,"eighty":-3.723653,"marketCap":31177648},{"date":"2024-12-20","current":-1.857563,"twenty":-8.853008,"median":-5.047673,"eighty":-3.619065,"marketCap":30202120},{"date":"2024-12-27","current":-1.764685,"twenty":-8.767209,"median":-5.021654,"eighty":-3.573099,"marketCap":28692014},{"date":"2025-01-03","current":-1.625368,"twenty":-8.642201,"median":-5.01517,"eighty":-3.513045,"marketCap":26426855},{"date":"2025-01-10","current":-1.838802,"twenty":-8.617491,"median":-5.008645,"eighty":-3.463472,"marketCap":29897078},{"date":"2025-01-17","current":-2.572725,"twenty":-8.517567,"median":-4.984374,"eighty":-3.373331,"marketCap":41829936},{"date":"2025-01-24","current":-2.370715,"twenty":-8.346557,"median":-4.965604,"eighty":-3.310726,"marketCap":38545455},{"date":"2025-01-31","current":-2.053117,"twenty":-8.284074,"median":-4.956607,"eighty":-3.212827,"marketCap":33381630},{"date":"2025-02-07","current":-2.238919,"twenty":-8.253306,"median":-4.940989,"eighty":-3.06772,"marketCap":36402592},{"date":"2025-02-14","current":-2.015957,"twenty":-8.160869,"median":-4.905782,"eighty":-3.026792,"marketCap":32777437},{"date":"2025-02-21","current":-2.043827,"twenty":-8.138995,"median":-4.896744,"eighty":-3.006493,"marketCap":33230582},{"date":"2025-02-28","current":-2.099568,"twenty":-8.099657,"median":-4.889484,"eighty":-2.934341,"marketCap":34136870},{"date":"2025-03-07","current":-2.146018,"twenty":-8.038556,"median":-4.87855,"eighty":-2.919724,"marketCap":34892111},{"date":"2025-03-14","current":-2.159953,"twenty":-8.005927,"median":-4.871913,"eighty":-2.813752,"marketCap":35118683},{"date":"2025-03-21","current":-1.801034,"twenty":-7.907089,"median":-4.866947,"eighty":-2.682321,"marketCap":29299223},{"date":"2025-03-28","current":-1.800101,"twenty":-7.780452,"median":-4.846639,"eighty":-2.622879,"marketCap":29284042},{"date":"2025-04-04","current":-1.82903,"twenty":-7.718678,"median":-4.817184,"eighty":-2.548971,"marketCap":29754652},{"date":"2025-04-11","current":-1.810366,"twenty":-7.669259,"median":-4.807351,"eighty":-2.494707,"marketCap":29451033},{"date":"2025-04-17","current":-1.735712,"twenty":-7.632006,"median":-4.806913,"eighty":-2.414832,"marketCap":28236557},{"date":"2025-04-25","current":-0.839954,"twenty":-7.607202,"median":-4.796544,"eighty":-2.376882,"marketCap":13664368},{"date":"2025-05-02","current":-0.521647,"twenty":-7.551589,"median":-4.752722,"eighty":-2.245719,"marketCap":8486148},{"date":"2025-05-09","current":-0.530045,"twenty":-7.466501,"median":-4.747756,"eighty":-2.177388,"marketCap":8622776},{"date":"2025-05-16","current":-0.505526,"twenty":-7.426042,"median":-4.707976,"eighty":-2.157166,"marketCap":7588954},{"date":"2025-05-23","current":-0.365063,"twenty":-7.386285,"median":-4.686306,"eighty":-2.149257,"marketCap":5480321},{"date":"2025-05-30","current":-0.393378,"twenty":-7.360388,"median":-4.668296,"eighty":-2.119771,"marketCap":5905387},{"date":"2025-06-04","current":-0.626387,"twenty":-7.341855,"median":-4.64843,"eighty":-2.102094,"marketCap":9403321}],"updateTime":1749197272646}}}